Organon Teknika signs distribution deal with Toyobo:
This article was originally published in Clinica
Organon Teknika has signed a sub-licensing agreement with Toyobo, granting the Japanese company non-exclusive rights to market Cangene's NASBA technology. The deal will cover infectious disease screening, and cancer and genetic testing in Japan. Cangene was recently granted a US patent for NASBA, covering RNA amplification and a European patent in June 1994 (see Clinica No 609, p 16). Organon is a partner of Cangene (Canada) and a subsidiary of Dutch company Akzo Nobel.
You may also be interested in...
With finite resources, the UK’s regulatory agency responsible for health care products is rapidly addressing COVID-19 medtech issues. But shifting its focus will cause delays elsewhere.
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.